Laboratory Abnormalities in Acne Patients Treated With Oral Isotretinoin: A Retrospective Epidemiological Study

Alajaji, Abdullah; Alrawaf, Faisal A.; Alosayli, Saleh I.; Alqifari, Hana N.; Alhabdan, Bader M.; al-Nasser, M

doi:10.7759/cureus.19031

Cited by 9 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TC was normal at baseline with 89.5% of patients and follow-up with 88.6%. 10 On the other hand, a retrospective study in Al Riyadh, KSA of 386 patients had high TC baseline readings as well as 2 follow-up readings (12.1%, 21.8%, and 18.7%, respectively). 14 Also, a study done in Sakarya University, Turkey, found no relation statistically between the third and sixth months of treatment in all parameters including cholesterol and TG.…”

Section: Discussionmentioning

confidence: 97%

“…Obesity was the major factor associated with high triglyceride levels, with a significant association between body weight and elevation of triglyceride levels. 10 Our aim in this study is to identify the prevalence of increased lipid levels during and after isotretinoin use in polyclinic patients of King Faisal University, Al-Ahsa, Saudi Arabia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Isotretinoin-Induced Dyslipidemia: a Single-Center Study in Saudi Arabia

Al Dhafiri,

Kaliyadan,

Almukhaimar

et al. 2024

PPA

View full text Add to dashboard Cite

Purpose Acne is a chronic inflammatory skin disease with a high prevalence in Saudi Arabia. Isotretinoin is used to treat severe, resistant nodulocystic acne. Side effects include joint discomfort, headache, mucosal dryness, and nose bleeds. Elevated lipids and liver enzymes have also been recorded. The study goal is to identify the prevalence of increased lipid levels during and after isotretinoin use. Patients and Methods This retrospective study was conducted in the dermatology polyclinic at King Faisal University, Al-Ahsa, Saudi Arabia. It included adults of different age groups diagnosed with acne vulgaris and treated with oral isotretinoin between January 2021 and December 2022. Parameters included baseline laboratory tests and follow-up laboratory results of cholesterol and triglycerides. Results Among 88 patients, 48.9% were aged 21–23 years, with females dominating. In total, 47.7% of patients started using isotretinoin at age 20 years or less, with starting doses ranging from 10 to 20 mg. Fifty percent of the patients had five months or more of treatment duration and only 6.8% of the patients had previously used isotretinoin. For the cholesterol and triglycerides, 87.5% of patients had normal pre-treatment with cholesterol and 90.9% with triglycerides, followed by 81.8% and 95.5% in the second reading, respectively. In the last reading, results were 77.3% for cholesterol and 94.3% for triglycerides. Conclusion The study found that most acne patients treated with isotretinoin had normal cholesterol and triglyceride levels at baseline, second, and last readings. The incidence of higher laboratory alterations was low, with 12.5% and 4.5% for cholesterol and triglycerides at baseline, and 18.2% and 3.4% at second, and 22.7% and 5.7% at last readings. Overall, age, gender, age of start of isotretinoin, isotretinoin dose, and previous use of isotretinoin are factors that could affect laboratory readings.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Isotretinoin-Induced Dyslipidemia: a Single-Center Study in Saudi Arabia

Al Dhafiri,

Kaliyadan,

Almukhaimar

et al. 2024

PPA

View full text Add to dashboard Cite

show abstract

“…Additionally, oral isotretinoin may lead to prolonged remission, even in the most severe cases. Unfortunately, isotretinoin is associated with a wide range of side effects, including serological lipid profile alterations, mucosal and skin dryness, liver function alteration, and neurological implications [ 31 ]. As a result of long-term therapy and severe forms of acne, scars can remain on patient skin and reduce their quality of life.…”

Section: Discussionmentioning

confidence: 99%

Topical Administration of Lactiplantibacillus plantarum (SkinDuoTM) Serum Improves Anti-Acne Properties

Podrini¹,

Schramm²,

Marianantoni³

et al. 2023

Microorganisms

View full text Add to dashboard Cite

The tailoring of the skin microbiome is challenging and is a research hotspot in the pathogenesis of immune-mediated inflammatory skin diseases such as acne. Commonly encountered preservatives used as functional ingredients have an impact on the skin microbiota and are known to inhibit the survival of skin commensal bacteria. The selected species is Lactiplantibacillus plantarum, formulated with natural enhancers for topical use (SkinDuoTM). Ex vivo human skin models were used as a test system to assess the strain viability which was then validated on healthy volunteers. SkinDuoTM showed increased viability over time for in vitro skin models and a stable viability of over 50% on healthy skin. The strain was tested on human primary sebocytes obtained from sebaceous gland rich areas of facial skin and inoculated with the most abundant bacteria from the skin microbiota. Results on human ex vivo sebaceous gland models with the virulent phylotype of Cutibacterium acnes and Staphylococcus epidermidis present a significant reduction in viability, lipid production, and anti-inflammatory markers. We have developed an innovative anti-acne serum with L. plantarum that mimics the over-production of lipids, anti-inflammatory properties, and improves acne-disease skin models. Based on these results, we suggest that SkinDuoTM may be introduced as an acne-mitigating agent.

show abstract

“…In case of significant abnormalities, further testing should be considered. 3 Reversible, mild elevation of transaminases occurs in 15% of patients on ISO. 4 Of interest, Duffy et al reported that isolated AST elevation might be an artifact of sample collection.…”

mentioning

confidence: 99%

“…6 Further, patients with higher body weight are at higher risk of elevated ALT level at the end of ISO course. 3 Pona et al noted that patients on ISO with Grade I AST and ALT elevations (greater than the upper normal limit [UNL] to three times UNL) were managed predominantly by maintaining the ISO dose (AST: 69%; ALT: 65%). Complete normalization was noted on average after 6 and 7 weeks for AST and ALT, respectively.…”

mentioning

confidence: 99%